-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 17, Fosun Pharma issued an announcement stating that recently, its holding subsidiary Chongqing Yaoyou Pharmaceutical Co.
Chongqing Yaoyou plans to carry out a phase I clinical trial of the new drug in China (excluding Hong Kong, Macao and Taiwan regions, the same below) when the conditions are met in the near future.
YP01001 capsule is an innovative small molecule chemical drug intended to treat advanced solid tumors; the preclinical development of YP01001 capsule is carried out by Fosun Pharma (including the company and its holding subsidiaries/units) and Shanghai WuXi AppTec New Drug Development Co.
As of the date of this announcement, the same type of YP01001 capsules that have been marketed in China include Lenvatinib mesylate capsules.
As of February 2021, Fosun Pharma has invested approximately RMB 33.